The ASCO Post

GLP-1 RAs May Have Little or No Effect on the Risk of Obesity-Related Cancers

A systematic review and meta-analysis sought to evaluate the risk for obesity-related cancers among patients with overweight, obesity, and/or type 2 diabetes using glucagon-like peptide-1 receptor agonists (GLP-1 RAs).

Camrelizumab Plus Rivoceranib vs Sorafenib for the First-Line Treatment of Unresectable Hepatocellular Carcinoma

Final analysis of a phase III study in unresectable hepatocellular carcinoma showed clinically meaningful improvements with the anti–PD-1/VEGFR2 combination compared with sorafenib in the first-line setting.

NSAIDs May Improve Survival in Postoperative ctDNA-Positive Patients With Colon Cancer

Circulating tumor DNA (ctDNA) levels may help to determine which patients with colon cancer could benefit from the addition of nonsteroidal anti-inflammatory drugs (NSAIDs), such as celecoxib, to chemotherapy following surgery, according to findings from a post hoc analysis of the CALGB/SWOG 80702 phase III trial.

Lifileucel Demonstrates Feasibility and Disease Stability in Advanced Head and Neck Squamous Cell Carcinoma

A single administration of the autologous tumor-infiltrating lymphocyte cell therapy led to disease stability in patients with recurrent and/or metastatic head and neck squamous cell carcinoma, even among patients whose disease had progressed or did not respond to multiple prior treatments, according to findings from a phase II trial.

Eliminating Barriers to Care for Patients With Intellectual and/or Developmental Disabilities

In this interview with The ASCO Post, Melissa Levin, MSW, LICSW, Senior Social Worker and Programmatic Specialist in the Neuro-Inclusive Oncology Care and Empowerment Program at Dana-Farber Cancer Institute, discussed the barriers to accessing patient-centric care, how communication between physician and patient can be improved, and how staff training in caring for patients with special needs can improve the treatment experience for patients and potentially disease outcome.

UICC’s World Cancer Declaration 2025–2035

The Union for International Cancer Control (UICC) published its World Cancer Declaration 2025–2035 framework, which urges governments and policymakers to take decisive action to reduce the global burden of cancer; promote equitable access to prevention, diagnosis, treatment, and survivorship care; and fully integrate cancer control programs into global health and sustainable development agendas.